These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 26051379)

  • 21. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
    J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.
    Chatterjee S; Ghose A; Sharma A; Guha G; Mukherjee D; Frankel R
    J Thromb Thrombolysis; 2013 Oct; 36(3):223-32. PubMed ID: 23212803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
    Roe MT; Armstrong PW; Fox KA; White HD; Prabhakaran D; Goodman SG; Cornel JH; Bhatt DL; Clemmensen P; Martinez F; Ardissino D; Nicolau JC; Boden WE; Gurbel PA; Ruzyllo W; Dalby AJ; McGuire DK; Leiva-Pons JL; Parkhomenko A; Gottlieb S; Topacio GO; Hamm C; Pavlides G; Goudev AR; Oto A; Tseng CD; Merkely B; Gasparovic V; Corbalan R; Cinteză M; McLendon RC; Winters KJ; Brown EB; Lokhnygina Y; Aylward PE; Huber K; Hochman JS; Ohman EM;
    N Engl J Med; 2012 Oct; 367(14):1297-309. PubMed ID: 22920930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.
    Oprea AD; Popescu WM
    J Cardiothorac Vasc Anesth; 2013 Aug; 27(4):779-95. PubMed ID: 23648080
    [No Abstract]   [Full Text] [Related]  

  • 25. [Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].
    Silber S; Helms TM; Garlichs C; Arntz HR; Weil J; Ince H; Klingenheben T; Hoffmann S; Boudriot E; Steiger H; Zugck C
    Dtsch Med Wochenschr; 2011 Apr; 136(15):782-5. PubMed ID: 21432747
    [No Abstract]   [Full Text] [Related]  

  • 26. Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.
    Jia M; Li Z; Chu H; Li L; Chen K
    Med Sci Monit; 2015 Apr; 21():1131-7. PubMed ID: 25893318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development.
    Tomasello SD; Tello-Montoliu A; Angiolillo DJ
    Expert Opin Investig Drugs; 2011 Jan; 20(1):119-33. PubMed ID: 21143003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute coronary syndromes: identifying the appropriate patient for prasugrel.
    Stephens JC; Askari AT
    Postgrad Med; 2012 Mar; 124(2):16-28. PubMed ID: 22437212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prasugrel: Clinical development and therapeutic application.
    Guerra DR; Tcheng JE
    Adv Ther; 2009 Nov; 26(11):999-1011. PubMed ID: 20020231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
    J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of bleeding in acute coronary syndromes with clopidogrel and prasugrel.
    Rodriguez L; Conde D; Lalor N; Elissamburu P; Trivi M
    Am J Emerg Med; 2013 Aug; 31(8):1287. PubMed ID: 23769852
    [No Abstract]   [Full Text] [Related]  

  • 32. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes.
    Quinlan DJ; Eikelboom JW; Goodman SG; Welsh RC; Fitchett DH; Théroux P; Mehta SR
    Eur Heart J; 2011 Sep; 32(18):2256-65. PubMed ID: 21624900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity.
    Lhermusier T; Lipinski MJ; Tantry US; Escarcega RO; Baker N; Bliden KP; Magalhaes MA; Ota H; Tian W; Pendyala L; Minha S; Chen F; Torguson R; Gurbel PA; Waksman R
    Am J Cardiol; 2015 Mar; 115(6):716-23. PubMed ID: 25728845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
    Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
    Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
    Tcheng JE; Mackay SM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):83-91. PubMed ID: 22316323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Will prasugrel supersede clopidogrel for acute coronary syndromes?
    Hankey GJ; Eikelboom JW; Langton PE
    Med J Aust; 2008 Apr; 188(7):381-2. PubMed ID: 18393737
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.
    Migliorini A; Valenti R; Parodi G; Marcucci R; Abbate R; Carrabba N; Gensini GF; Antoniucci D
    Am J Cardiol; 2013 Dec; 112(12):1843-8. PubMed ID: 24063827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prasugrel: a critical comparison with clopidogrel.
    Reinhart KM; White CM; Baker WL
    Pharmacotherapy; 2009 Dec; 29(12):1441-51. PubMed ID: 19947804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
    Darlington A; Tello-Montoliu A; Rollini F; Ueno M; Ferreiro JL; Patel R; Desai B; Guzman LA; Bass TA; Angiolillo DJ
    Thromb Haemost; 2014 Feb; 111(2):258-65. PubMed ID: 24154863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.